In non-small cell lung cancer and thyroid cancer cells, CMLD-2 treatment reduces the mRNA expression of HuR or competitively binds to HuR, thereby down-regulating target mRNA.164. The gene discussed is ELAVL1; the disease is thyroid gland carcinoma.